Your browser doesn't support javascript.
loading
A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study).
Grünwald, Viktor; Hilser, Thomas; Meiler, Johannes; Goebell, Peter J; Ivanyi, Philipp; Strauss, Arne; Hartmann, Arndt; Bedke, Jens; Bergmann, Lothar.
Afiliação
  • Grünwald V; Interdisciplinary Genitourinary Oncology at the West-German Cancer Center, Clinic for Internal Medicine (Tumor Research) and Clinic for Urology, University Hospital Essen, Essen, Germany.
  • Hilser T; Internal Medicine (Tumor Research) and Clinic for Urology, University Hospital Essen, Essen, Germany, thomas.hilser@uk-essen.de.
  • Meiler J; Klinik Dr. Hancken GmbH, MVZ Oncology, Stade, Germany.
  • Goebell PJ; Clinic for Urology, University Hospital Erlangen, Erlangen, Germany.
  • Ivanyi P; Clinic for Hematology, Hemostasis, Oncology and Stemn Cell Transplantation, Medical School Hanover, Hanover, Germany.
  • Strauss A; Clinic for Urology, University Hospital Göttingen, Göttingen, Germany.
  • Hartmann A; Pathology, University Hospital Erlangen, Erlangen, Germany.
  • Bedke J; Department of Urology, Eberhard Karls University Tübingen, Tübingen, Germany.
  • Bergmann L; Medical Clinic 2, University Hospital Frankfurt, Frankfurt, Germany.
Oncol Res Treat ; 45(5): 272-280, 2022.
Article em En | MEDLINE | ID: mdl-35045416
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article